Estimation of the impact of genital warts on health-related quality of life

S Woodhall, T Ramsey, C Cai, S Crouch, Mark Jit, Y Birks, WJ Edmunds, R Newton, CJN Lacey

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

OBJECTIVES: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV types 16 and 18. In anticipation of HPV vaccine implementation, the impact of genital warts on health-related quality of life (HRQoL) was measured to assess the potential benefits of the quadrivalent over the bivalent vaccine. METHODS: Genitourinary medicine clinic patients aged 18 years and older with a current diagnosis of genital warts were eligible; 81 consented and were interviewed by a member of the research team. A generic HRQoL questionnaire, the EQ-5D (comprising EQ-5D index and EQ visual analogue scale (VAS) scores) and a disease-specific HRQoL instrument, the CECA10, were administered. Previously established UK population norms were used as a control group for EQ-5D comparisons. RESULTS: Cases (with genital warts) had lower EQ VAS and EQ-5D index scores than controls. After adjusting for age a mean difference between cases and controls 30 years of age and under (n = 70) of 13.9 points (95% CI 9.9 to 17.6, p
Original languageEnglish
Pages (from-to)161-166
Number of pages6
JournalSexually Transmitted Infections
Volume84
Issue number3
DOIs
Publication statusPublished - 1 Jun 2008

Fingerprint

Dive into the research topics of 'Estimation of the impact of genital warts on health-related quality of life'. Together they form a unique fingerprint.

Cite this